FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
81796137 ABSTRACT Compounds represented by formula (I) N-oxides thereof, pharmaceutically acceptable salts or solvates thereof, or glucuronide derivatives thereof, or co-crystals thereof, R3 R2 R5a / ____________________________________ ( R5b R1 // N z / R4 R6 _______________________________ X Y (I)...
Saved in:
Main Authors | , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
19.07.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 81796137 ABSTRACT Compounds represented by formula (I) N-oxides thereof, pharmaceutically acceptable salts or solvates thereof, or glucuronide derivatives thereof, or co-crystals thereof, R3 R2 R5a / ____________________________________ ( R5b R1 // N z / R4 R6 _______________________________ X Y (I) ' in particular dihydro-1H-pyrano[4',3':4,5limidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-cldipyridine, dihydro-1H-pyrano[3',4':4,5limidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,51imidazo[1,2-a1pyridine, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. Date Recue/Date Received 2021-09-22
La présente invention concerne une série de dérivés d'imidazole tricyliques fusionnés substitués, en particulier la dihydro- 1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine, la 1,2,3,4-tétrahydroimidazo[1,2-a:5,4- c']dipyridine, la dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine et la tétrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine et leurs analogues, qui sont des modulateurs puissants de l'activité du TNFa humain, et offrent en conséquence des avantages dans le traitement et/ou la prévention de diverses affections chez l'homme, notamment les maladies autoimmunes et inflammatoires ; les maladies neurologiques et neurodégénératives ; les troubles de la douleur et nociceptifs ; les maladies cardiovasculaires ; les troubles métaboliques ; les maladies oculaires ; et les maladies oncologiques. |
---|---|
Bibliography: | Application Number: CA20142932057 |